Download App

Log in to access Online Inquiry
Company Overview More
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
CEO: Forster M.B.A., Ph.D., Eliot Richard
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > FSTX F-star Therapeutics > Detailed Quotes

FSTX F-star Therapeutics

2.540-0.080-3.05%
Close 05/26 20:00 ET
High
2.664
Open
2.590
Turnover
324.55K
Low
2.510
Pre Close
2.620
Volume
126.94K
Market Cap
54.76M
P/E(TTM)
Loss
52wk High
9.710
Shares
21.56M
P/E(Static)
Loss
52wk Low
2.070
Float Cap
49.69M
Bid/Ask %
20.00%
Historical High
75.720
Shs Float
19.56M
Volume Ratio
2.84
Historical Low
2.070
Dividend TTM
--
Div Yield TTM
--
P/B
0.62
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.65%
Amplitude
5.86%
Avg Price
2.556
Lot Size
1
Float Cap
49.69M
Bid/Ask %
20.00%
Historical High
75.720
Shs Float
19.56M
Volume Ratio
2.84
Historical Low
2.070
Dividend TTM
--
P/B
0.62
Dividend LFY
--
Turnover Ratio
0.65%
Amplitude
5.86%
Avg Price
2.556
Lot Size
1
Price Forecast

No Data

News

Comment